Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 7.

Rehefeldt-Erne, Susanne; Nägeli, Mirjam C; Winterton, Nina; Felderer, Lea; Weibel, Lisa; Hafner, Jürg; Dummer, Reinhard (2016). Nevoid Basal Cell Carcinoma Syndrome: Report from the Zurich Nevoid Basal Cell Carcinoma Syndrome Cohort. Dermatology, 232(3):285-292.

Mangana, Joanna; Felderer, Lea; Cheng, Phil; French, Lars E; Dummer, Reinhard; Schad, Karin (2015). Diffuse cutaneous melanosis associated with malignant melanoma. Annals of dermatology, 27(6):780-781.

Otsuka, Atsushi; Dreier, Jil; Cheng, Phil F; Nägeli, Mirjam; Lehmann, Holger; Felderer, Lea; Frew, Ian J; Matsushita, Shigeto; Levesque, Mitchell P; Dummer, Reinhard (2015). Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma. Clinical Cancer Research:1289-1297.

Felderer, Lea; Schmid-Grendelmeier, Peter (2015). Baseline serum tryptase levels increase within normal values with age and depend on gender. Dermatologica Helvetica, 27(7):26-31.

Dreier, Jil; Dummer, Reinhard; Felderer, Lea; Nägeli, Mirjam; Gobbi, Sharon; Kunstfeld, Rainer (2014). Emerging drugs and combination strategies for basal cell carcinoma. Expert opinion on emerging drugs, 19(3):353-365.

Dummer, Reinhard; Goldinger, Simone M; Turtschi, Christian P; Eggmann, Nina B; Michielin, Olivier; Mitchell, Lada; Veronese, Luisa; Hilfiker, Paul René; Felderer, Lea; Rinderknecht, Jeannine D (2014). Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer, 50(3):611-621.

Dreier, Jil; Felderer, Lea; Barysch, Marjam; Rozati, Sima; Dummer, Reinhard (2013). Basal cell carcinoma: a paradigm for targeted therapies. Expert Opinion on Pharmacotherapy, 14(10):1307-1318.

This list was generated on Sun Nov 19 02:31:40 2017 CET.